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Abstract
Objectives Current guidelines provide limited evidence
as to which patients with urinary tract infection (UTI)
require hospitalisation. We evaluated the currently used
triage routine and tested whether a set of criteria including
biomarkers like proadrenomedullin (proADM) and urea
have the potential to improve triage decisions.
Methods Consecutive adults with UTI presenting to our
emergency department (ED) were recruited and followed
for 30 days. We defined three virtual triage algorithms,
which included either guideline-based clinical criteria,
optimised admission proADM or urea levels in addition to
a set of clinical criteria. We compared actual treatment
sites and observed adverse events based on the physician
judgment with the proportion of patients assigned to
treatment sites according to the three virtual algorithms.
Adverse outcome was defined as transfer to the intensive
care unit (ICU), death, recurrence of UTI or rehospitali-
sation for any reason.
Results We recruited 127 patients (age 61.8 ± 20.8
years; 73.2 % females) and analysed the data of 123
patients with a final diagnosis of UTI. Of these 123
patients, 27 (22.0 %) were treated as outpatients. Virtual
triage based only on clinical signs would have treated only
22 (17.9 %) patients as outpatients, with higher proportions
of outpatients equally in both biomarker groups (29.3 %;
p = 0.02). There were no significant differences in adverse
events between outpatients according to the clinical
(4.5 %), proADM (2.8 %) or urea groups (2.8 %). The
mean length of stay was 6.6 days, including 2.2 days after
reaching medical stability.
Conclusions Adding biomarkers to clinical criteria has
the potential to improve risk-based triage without impair-
ing safety. Current rates of admission and length of stay
could be shortened in patients with UTI.
Keywords Urinary tract infection  Triage  Biomarkers
Introduction
Urinary tract infection (UTI) is considered to be the most
common bacterial infection in humans [1]. In adults aged
65 years or older, UTI is the second most common cause of
infectious disease-related hospitalisations [2], with almost
eight million annual consultations in emergency depart-
ments (EDs) in the USA alone [3]. The decision as to
whether to admit a patient might be one of the most
important clinical assessments made by physicians during
the entire course of illness for patients with UTI. It has a
direct influence on the intensity of laboratory testing,
microbiological evaluation, antibiotic therapy and cost of
treatment. Older patients who are hospitalised are more
vulnerable to become impaired or lose their functional and
self-care abilities, possibly leading to inpatient treatment or
increased length of stay (LOS) [4]. Outpatient treatment,
especially in elderly, fragile patients, is less expensive and
carries a lower risk of hospital-acquired disability and
nosocomial infections, including Clostridium difficile-
associated diarrhoea [5]. Despite a low risk according to
clinical severity scores, many patients with community-
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acquired infectious diseases are hospitalised for medical
co-morbidities and psychosocial reasons [6, 7]. In a health
system with a well-organised primary care system, patients
with UTIs who were carefully selected for treatment at
home according to clear guidelines did not have major
complications [8].
The current guidelines for patients with UTI either lack
specific criteria for the requirement of hospital admission
and appropriateness of discharge or include fairly vague
criteria and subjective parameters such as high fever, flank
pain or severe malaise. These guidelines are based, rather,
on expert opinion than strict medical evidence, with limited
efficiency and safety profiles [9–15]. Most of these clinical
criteria are fairly subjective and difficult to graduate or
measure.
Biomarkers are objective, dynamic and easily measur-
able. Numerous studies have shown distinct evidence
supporting the use of biomarkers to improve the diagnosis
of bacterial infections and to guide antibiotic therapy
[16–19]. Proadrenomedullin (proADM) was the most
accurate biomarker for prognostic assessment [20, 21].
We recently reported improved performance of the
combination of proADM with the prognostic CURB-65
score for predicting mortality and adverse outcomes in
patients with lower respiratory tract infection (LRTI)
compared to the CURB-65 score alone [22]. Biomarker-
enhanced triage might have great potential to avoid not-
indicated hospital admissions and shorten the LOS [23].
Analogous studies do not yet exist for UTI, despite the
apparent need for improved triage in daily clinical routine.
Here, we extended our concept from LRTI to UTI and
assessed the prognostic value of initial concentrations of
proADM or urea in patients presenting to an ED with UTI.
This was based on the hypothesis that the measurement of
biomarkers provides additional prognostic information
over clinical criteria alone regarding hospitalisation
requirement. We also assessed whether the LOS for hos-
pitalised patients with UTI could be shortened by applying
objective stability criteria.
Materials and methods
Subjects and study design
This was a prospective observational quality control survey
at the Kantonsspital Aarau, Switzerland, from January to
September 2011. We consecutively enrolled all adults (age
C18 years) presenting to our ED with acute (\28 days)
symptoms typical for UTI. The inclusion criterion was an
established diagnosis of UTI on admission. There were no
exclusion criteria.
The triage, diagnostic and therapeutic judgments were
taken by the treating physician without any influence by the
study team, knowledge of virtual algorithms or of proADM
levels. Patients were clinically observed from admission to
discharge. Demographic, clinical and microbiological
information was collected by the study team. Medical
evaluation was performed daily in order to verify clinical
stability. If a patient remained in hospital despite being
medically stable, the physician in charge was asked to
provide an overruling reason. Telephone interviews were
performed with all patients 30 days after enrolment.
The local Institutional Review Board (Kantonale Ethi-
kkommission Aargau) classified this study as an observa-
tional quality surveillance and waived the need for patient
informed consent.
Methods of proADM measurement
ProADM was batch-measured in EDTA serum routinely
collected on admission with a sandwich immunoassay
(MR-ProADM, Thermo Fisher Scientific-BRAHMS AG,
Hennigsdorf, Germany), with an analytical detection limit
of 0.08 nmol/l and a functional assay sensitivity of
0.12 lg/l [24]. The results were not available at the time of
hospitalisation and, thus, physicians and patients were
blinded to these results.
Definitions
UTI was diagnosed in the presence of at least one clinical
symptom of cystitis or pyelonephritis and at least one
urinary criterion: C105 colony-forming units (CFU)/ml and
B2 different organisms in the culture (if not pretreated with
antibiotics) [15], pyuria ([20 leukocytes/ll) [25] or urine
positive for leukocyte esterase and/or nitrites by dipstick
[26]. Clinical symptoms of cystitis (lower UTI) comprised
dysuria, frequency, urgency, suprapubic pain and/or
hematuria [27]; signs and symptoms of pyelonephritis
(upper UTI) comprised fever ([38 C), chills, flank pain,
costovertebral angle tenderness and nausea/vomiting,
regardless of the presence of symptoms of cystitis [28, 29].
Uncomplicated UTI was restricted to female non-preg-
nant patients \70 years of age. Conversely, a complicated
UTI was defined according to the literature [10, 12, 14] as
an infection associated with any condition or the presence
of an underlying disease which increases susceptibility or
reduces host response to infections: male sex, elderly age
([70 years), hospital acquisition, pregnancy, indwelling
urinary catheter, recent urinary tract intervention, func-
tional or anatomical abnormality of the urinary tract, recent
antimicrobial use, symptoms for [7 days at presentation,
diabetes mellitus or immunosuppression.
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Using the above criteria, we distinguished four diagnoses:
uncomplicated cystitis, complicated cystitis, uncomplicated
pyelonephritis and complicated pyelonephritis. Patients were
classified according to the final diagnosis and as ‘other diag-
nosis’ if the final diagnosis was different from UTI.
Based on a literature review, we chose the six most
consistently mentioned hospitalisation criteria (Table 1).
Medical stability was derived from the Infectious Diseases
of American Society (IDSA) criteria for LRTI and adapted
to UTI (Table 2). Patients were considered to be eligible
for discharge from acute medical care if they were clini-
cally stable for at least 24 h and did not require any further
acute medical treatment.
Adverse outcomes included death, transfer to the
intensive care unit (ICU), recurrence of UTI or rehospi-
talisation for any reason within 30 days of enrolment.
Independently of the actually observed treatment site
allocation, every enrolled patient was retrospectively and
virtually allocated to inpatient or outpatient treatment using
three different triage algorithms (Fig. 1). The term ‘virtual
allocation’ represents the treatment site (i.e. hospital
admission or ambulant care) which should have been
chosen according to the particular triage algorithm.
In the first virtual triage algorithm (guideline-concordant
triage), all six admission criteria (Table 1) were used to
assess the need for hospital admission. If any of these were
present, inpatient treatment was recommended, otherwise
outpatient treatment was following. This treatment site
allocation was called ‘clinical virtual triage’ and all ‘clin-
ical virtual’ inpatients and outpatients represented the
‘clinical virtual group’.
While criteria 2–6 are objective, the first criterion in
Table 1 (severe illness, high fever, costovertebral angle
tenderness, severely impaired health) appears subjective.
To enhance the objectivity of the treatment site allocation,
we replaced, in the second and third classifications, the first
criterion with levels of the biomarkers proADM and urea,
respectively. We determined the most suitable cut-off
values using the best performance for both efficacy and
safety.
In the second virtual triage algorithm (‘proADM virtual
triage’), proADM replaced the first hospitalisation crite-
rion: if any of criteria 2–6 were present or proADM
C1.5 nmol/l, the patient was virtually allocated to inpatient
care and otherwise to outpatient care. This classification
was called ‘proADM virtual triage’ and the patients rep-
resented the ‘virtual proADM group’.
In the third virtual triage algorithm (‘urea virtual tri-
age’), urea was used instead of the first admission criterion:
if any of criteria 2–6 were present or urea C14 mmol/l, the
patient was virtually allocated to inpatient care and other-
wise to outpatient care. This classification was called ‘urea
virtual triage’ and the patients represented the ‘urea virtual
group’.
The selection of treatment sites made in real life by the
physician in charge was called ‘actual triage’ and the
patients represented the ‘actual treatment group’. This real
group and the three virtual ones contain the same number
of patients (equal to the number of enrolled patients), but
the distribution of inpatient and outpatient treatment
between the groups vary.
Endpoints
Our primary endpoint was to compare the percentages of
patients eligible for outpatient treatment between the three
virtual triage algorithms. Secondary endpoints were the
determination of hospitalisation length before and after
reaching medical stability and prediction of adverse events
by the different triage algorithms.
Statistical analysis
Discrete variables were expressed as counts (percentage)
and continuous variables as medians or means and standard
deviations or interquartile range, as appropriate. The
comparison between qualitative variables was performed
by Fisher’s exact test or the Mantel–Haenszel v2 test, as
appropriate, and for quantitative normally distributed data
by Student’s t-test. For data not normally distributed, but
with a similar shape, the Mann–Whitney U-test was used.
Statistical analyses were performed using SAS (SAS
Institute Inc., Cary, NC, USA) and Epi Info (version 3.5.1,
CDC, Atlanta, GA, USA). All testing was two-tailed and
p-values \0.05 were considered to indicate statistical
significance.
Table 1 Criteria for admission
1. Severe illness, high fever, costovertebral angle tenderness,
severely impaired health
2. Inability to take oral medications or fluids with dehydration
3. Questionable patient compliance
4. Pregnancy
5. Complications of pyelonephritis: papillary necrosis, intrarenal/
perirenal abscess, emphysematous pyelonephritis
6. Evidence of acute serious co-morbidity that necessitates
hospitalisation
Table 2 Criteria for medical stability
1. Stable vital signs (T B 37.8 C, pulse B 100/min, respiratory
rate B 24/min, systolic blood pressure C 90 mmHg)
2. Feasibility of oral intake
3. Return to baseline mental status
4. No evidence of acute serious co-morbidity that necessitates
hospitalisation
The potential impact of biomarker-guided triage decisions 801
123
Results
Baseline characteristics
A total of 127 patients (mean age 61.8 ± 20.8 years;
73.2 % females) were enrolled in our study. Their baseline
characteristics are shown in Table 3. The 123 patients with
a final diagnosis of UTI, comprising nine with uncompli-
cated and 32 with complicated cystitis, 20 with uncom-
plicated and 62 with complicated pyelonephritis, were
further analysed. Twenty-seven patients (22 %) were
treated as outpatients and 96 (78 %) were hospitalised. The
distribution of hospitalisation criteria is shown in Table 4.
The serum levels of biomarkers on admission were sig-
nificantly higher in inpatients than in outpatients (median
proADM 1.25 vs. 0.53 nmol/l, p \ 0.001, median urea 6.4
vs. 4.5 mmol/l, p \ 0.01) (Fig. 2).
Allocation of the virtual treatment site
According to only clinical criteria (‘clinical virtual group’),
21 of 123 patients (17.1 %) would qualify for outpatient
treatment and 102 (82.9 %) should be admitted to the
hospital. Applying the ‘proADM virtual triage’ or ‘urea
virtual triage’, 36 (29.3 %) patients would not require
hospitalisation and 87 (70.7 %) patients should be hospi-
talised (Fig. 3). As shown in Table 5, 10 of 36 (27.8 %)
patients who would be eligible for outpatient treatment
according biomarker-enhanced triage were admitted to the
hospital in real life.
Comparing the virtual algorithms, the ‘proADM virtual
triage’ and ‘urea virtual triage’ would have allowed sig-
nificantly more outpatient treatments than would have
occurred using ‘clinical virtual triage’ (p = 0.02 for both,
Fig. 3).
The difference in the proportion of outpatients between
‘actual triage’ and ‘proADM virtual triage’ with respect to
‘urea virtual triage’ was not statistically significant
(p = 0.19, Fig. 3).
Microbiological data and antibiotic use
The results of urine cultures were available for 120 patients
(98 %). The most common pathogen was Escherichia coli
(58 %), followed by Klebsiella species (5 %). Mixed flora
was found in 6 % of cultures and, in 19 % of all cases,
there was no significant bacteriuria; 74 % of the latter were
pre-treated with antibiotics. The spectra of pathogens for
inpatients and outpatients were similar (Table 6).
Blood cultures on admission were performed for 82
patients (67 %). In the case of admission, 77 % of patients
underwent blood culture sampling with 15 % having bac-
teraemia. Blood cultures were performed in 30 % of out-
patients, with only one positive result (4 %).
All patients were treated with an antibiotic. Fluoro-
quinolones were used for 19 patients (15.7 %), penicillins
Fig. 1 Algorithm for virtual
triage decisions on admission
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for 19 patients (15.7 %), cephalosporins for 60 patients
(48.8 %) and trimethoprim–sulphamethoxazole for 25
patients (20.3 %). Forty-four patients (35.8 %) were ini-
tially treated orally and the other 79 (64.2 %) received at
least one antibiotic dose intravenously. Looking at inpa-
tients and outpatients separately, significantly (p \ 0.001)
more inpatients were treated intravenously compared to
outpatients: 75 of 96 (78.1 %) versus 4 of 27 (14.8 %).
All four outpatients who received intravenous antibiot-
ics and eight of the inpatients were given a single shot of
ceftriaxone, followed by other antibiotics orally.
Length of stay and time to medical stability
Patients who were admitted to the hospital stayed for, on
average, 6.6 days in the hospital. The mean time to medical
stability was 4.4 days; thus, patients remained hospitalised
for 2.2 days after reaching medical stability. All patients
treated as outpatients in real life left the emergency
department medically stable.
Adverse events
Complications were present in 25 (20.3 %) of 123 patients;
the breakdown according to the different virtual triages is
shown in Table 7. Four patients (3.3 %), all of them treated as
inpatients, died. All of them would have been triaged to
inpatient care according to all three virtual triage algorithms.
There were significantly (p = 0.02) fewer adverse
events encountered in patients treated at home (3.7 %) than
in hospitalised patients (25 %). There were no statistically
significant differences in the adverse events between out-
patients according to the clinical (4.8 %), proADM (2.8 %)
or urea groups (2.8 %). We found no statistically signifi-
cant differences for adverse events between real life and
virtual triages with biomarkers. Using the virtual algo-
rithms with proADM or urea, the difference in the number
of adverse events between outpatients and inpatients was
statistically significant (p = 0.002), but this was not the
case in the clinical virtual group (p = 0.08).
The admission levels of proADM were significantly
higher in patients with an adverse event within 30 days
than those without (median 1.67 vs. 1.00 nmol/l, p =
0.003), whereas this difference was not significant for urea
(median 6.4 vs. 5.6 mmol/l, p = 0.267) (Fig. 4).
Discussion
Our primary endpoint was to investigate the potential
impact of using biomarkers for the decision regarding
hospital admission in patients with UTI. Herein, we present
four key findings. First, both proADM and urea levels wereT
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higher for inpatients than outpatients. Second, only
proADM levels were higher in those patients with adverse
events compared to those without. Third, as compared to
current guidelines, using either proADM or urea instead of
rather subjective hospitalisation criteria as part of a clinical
algorithm would have allowed a higher proportion of
patients to be safely treated as outpatients. Finally, we
demonstrate that patients with UTI are hospitalised for
more than 2 days after they have reached medical stability.
The combination of proADM or urea with clinical cri-
teria increases the proportion of outpatients compared to
current triage practice, and even more so if the current
guidelines had been strictly adhered to. This result was
achieved without an increase of adverse events. Another
12 % of patients could be treated at home using biomarker-
enhanced triage.
The hospitalisation rate of 78 % among our patients was
higher than that reported by Claessens et al. [30] and in the
study of Elkharrat et al. [31], where only 26 and 13 % of
patients, respectively, were admitted. The main reason for
this difference was likely the fact that our cohort was
markedly older and sicker. In the two previous studies, the
mean age for outpatients was 33 or 34.1 years and for
inpatients, it was 46 or 55.7 years, respectively. Our out-
patients had a median age of 41 years and our inpatients
had a median age of 72 years, respectively, and 33 and
Table 4 Distribution of criteria for hospitalisation
Hospitalisation criteria All
(n = 123)
Uncompl.
Cyst. (n = 9)
Compl. Cyst.
(n = 32)
Uncompl. PN
(n = 20)
Compl. PN
(n = 62)
1. Severe illness, high fever, costovertebral angle tenderness,
severely impaired health
83 0 10 16 57
2. Inability to take p.o. medications or fluids with dehydration 80 1 17 11 51
3. Questionable patient compliance 4 0 1 1 2
4. Pregnancy 0 0 0 0 0
5. Complications of pyelonephritis: papillary necrosis, intrarenal/
perirenal abscess, emphysematous pyelonephritis
0 0 0 0 0
6. Evidence of acute serious co-morbidity that necessitates
hospitalisation
32 0 16 2 14
Uncompl. uncomplicated, Compl. complicated, Cyst. cystitis, PN pyelonephritis
Fig. 2 Distribution of
biomarkers on admission for
inpatients and outpatients. The
lower and upper limits of the
boxes indicate the 1st and 3rd
quartiles, respectively; the
horizontal line in the box
represents the median value
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88 % had at least one co-morbidity, respectively, which
was more than in the other studies. This picture corre-
sponds to the situation in the EDs of well-developed
countries where patients are becoming older and have more
impaired health [32, 33]. Another reason for the high
hospitalisation rate might have been the preselection made
by family physicians, who decided whether to refer the
patient to an ED or not. In Switzerland, many patients
consult the family physician first; thus, most patients who
can be treated in the ambulant setting never present to the
ED.
In a comparable study of van Nieuwkoop et al. [8]
(similar population with a median age 64 years, 61 % with
co-morbidities), 86 % of patients presenting to the ED
were hospitalised using triage which was based only on
clinical criteria. Using our clinical virtual algorithm, the
proportion of inpatients would be comparable at 83 %,
while more patients would have been treated outside the
hospital using biomarker-enhanced triage in our study.
We found only a non-significant trend for less inpatient
assignment with the biomarker virtual triage (71 %) com-
pared to our current actual triage (78 %). This finding
could be based on the fact that our physicians in charge had
already participated in a similar trial for optimised triage in
LRTI [23] and, thus, were sensitized for increasing the
outpatient ratio. Furthermore, our hospital performs regu-
larly at or beyond maximal bed capacity, leading to fre-
quent bed shortages and more restrictive hospitalisations
than recommended by the guidelines.
The 30-day mortality rate in our study is similar to
recently reported rates [8, 34]. The overall mortality was
3 %: all outpatients stayed alive, whereas 4 % of inpatients
died. We found no differences for adverse events between
real life and virtual triages with biomarkers. In the Pro-
HOSP study [35], the fear of adverse outcome outside of
hospital was one of the most important reasons for hospital
admission for LRTI. None of the patients who would have
been assigned ambulatory care according to our proposed
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Actual Treatment Clinical Virtual
Group
proADM Virtual
Group
Urea Virtual Group
Inpatient Outpatient
p=0.34
p=0.02
p=0.02 
Fig. 3 Site of care by actual triage and the virtual triage algorithms
Table 5 Distribution of actual and suggested virtual treatment sites
Inpatient Outpatient
Clinical virtual group
Suggested virtual treatment site: no. (%) 102 (82.9) 21 (17.1)
Actual treatment site: inpatient/outpatient 94/8 2/19
proADM virtual group
Suggested virtual treatment site: no. (%) 87 (70.7) 36 (29.3)
Actual treatment site: inpatient/outpatient 86/1 10/26
Urea virtual group
Suggested virtual treatment site: no. (%) 87 (70.7) 36 (29.3)
Actual treatment site: inpatient/outpatient 86/1 10/26
Table 6 Urine culture findings
Uropathogen:
no. (%)
All patients
(n = 123) (%)
Inpatients
(n = 96) (%)
Outpatients
(n = 27) (%)
Uncompl. Cyst.
(n = 9) (%)
Compl. Cyst.
(n = 32) (%)
Uncompl. PN
(n = 20) (%)
Compl. PN
(n = 62) (%)
E. coli 71 (58) 56 (58) 15 (56) 4 (44) 17 (53) 16 (80) 34 (55)
Klebsiella spp. 6 (5) 6 (6) 0 0 0 0 6 (10)
Enterococcus
faecalis
3 (2) 2 (2) 1 (4) 0 1 (3) 0 2 (3)
Pseudomonas
aeruginosa
2 (2) 2 (2) 0 0 0 0 2 (3)
Citrobacter
spp.
2 (2) 1 (1) 1 (4) 0 1 (3) 0 1 (2)
Streptococcus
spp.
2 (2) 2 (2) 0 0 2 (6) 0 0
Other 4 (3) 3 (3) 1 (4) 1 (11) 0 0 3 (5)
Mixed flora 7 (6) 6 (6) 1 (4) 1 (11) 3 (9) 0 3 (5)
No growth 23 (19) 18 (19) 5 (19) 1 (11) 8 (25) 3 (15) 11 (18)
Uncompl. uncomplicated, Compl. complicated, Cyst. cystitis, PN pyelonephritis
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biomarker-enhanced triage experienced death, ICU
admission or rehospitalisation, and only 1 (2.8 %) of the
proposed outpatients had a relapse. While it might be
argued that these adverse events might have been pre-
vented by the actual inpatient care, the observation of
higher proADM levels in those patients with adverse out-
comes supports the prognostic utility of proADM. Despite
formally failing to achieve significant differences between
patients with and those without adverse events for urea
levels, a urea-enhanced algorithm would have triaged
patients identically to a proADM-based triage. As urea is
more affected by renal function, proADM might be more
useful in patients with chronic renal insufficiency. The
adverse events rate between inpatients and outpatients in
the clinical virtual group was similar, suggesting that the
triage based only on clinical criteria might be inferior to
biomarkers in distinguishing between high-risk and low-
risk patients. Biomarkers alone also do not reliably help
physicians in their decision-making process of the
requirement for admission, even though neither urea nor
proADM were evaluated in that study by Claessens et al.
[30]. Conversely, adding biomarkers to clinical criteria, i.e.
combining the two powerful physicians’ instruments, could
improve the prognostic assessment.
We also demonstrated that the LOS for hospitalised
patients could be substantially shortened. The mean length
Table 7 Adverse events stratified for the different virtual triage algorithms
Actual treatment group Clinical virtual group ProADM virtual group Urea virtual group Overall
(n = 123)
Outpatient
(n = 27)
Inpatient
(n = 96)
Outpatient
(n = 21)
Inpatient
(n = 102)
Outpatient
(n = 36)
Inpatient
(n = 87)
Outpatient
(n = 36)
Inpatient
(n = 87)
Death: no. (%) 0 4 (4.2) 0 4 (3.9) 0 4 (4.6) 0 4 (4.6) 4 (3.3)
ICU admission:
no. (%)
0 4 (4.2) 0 4 (3.9) 0 4 (4.6) 0 4 (4.6) 4 (3.3)
Relapse: no. (%) 1 (3.7) 12 (12.5) 1 (4.8) 12 (11.8) 1 (2.8) 12 (13.8) 1 (2.8) 12 (13.8) 13 (10.6)
Rehospitalisation:
no. (%)
0 10 (10.4) 0 10 (9.8) 0 10 (11.5) 0 10 (11.5) 10 (8.1)
Related to UTI 0 4 (4.2) 0 4 (3.9) 0 4 (4.6) 0 4 (4.6) 4 (3.3)
Unrelated to UTI 0 6 (6.3) 0 6 (5.9) 0 6 (6.9) 0 6 (6.9) 6 (4.9)
Any: no. (%) 1 (3.7) 24 (25) 1 (4.8) 24 (23.5) 1 (2.8) 24 (27.6) 1 (2.8) 24 (27.6) 25 (20.3)
p = 0.02 p = 0.08 p = 0.002 p = 0.002
Fig. 4 Distribution of
biomarkers on admission for
patients with and without
adverse events. The lower and
upper limits of the boxes
indicate the 1st and 3rd
quartiles, respectively; the
horizontal line in the box
represents the median value
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of hospitalisation for our population was 6.6 days. In the
recent work published by Elkharrat et al. [31], the mean
LOS was 19 days. We observed that patients stayed
2.2 days longer after being medically stable. Thus, the
stability criteria should be regularly assessed throughout
the hospitalisation (e.g. daily) in order to facilitate a timely
discharge and avoidance of unnecessarily longer hospital-
isation. Prolonged hospitalisations have been associated with
increased risk of nosocomial infections, falls, medication side
effects and worsening or new onset of frailty [4].
There are limitations of this observational survey. We
collected data from only one hospital and, so, the external
validity of the results may be limited. We computed a
composite of adverse events as an endpoint and chose the
composite to create clinically meaningful outcome in light
of sample size considerations. The triages being compared
were virtual. This study design gave us the opportunity to
evaluate the different triages using a significantly smaller
sample size. The outcome comparison is hypothetical as
well. As the classes and the route of application of anti-
biotics differ significantly between inpatients and outpa-
tients, on first sight, it appears difficult to draw conclusions
on the virtual outcome. Thirty-six patients would be eli-
gible for outpatient treatment according to the virtual triage
with biomarkers. Twenty-six of them were outpatients in
real life and ten were admitted to the hospital. Four of the
former and two of the latter (p = 0.74) received a single
shot of ceftriaxone in the ED and, thereafter, the regimen
was switched to oral antibiotics. Such a course of therapy
was shown to be safe in different studies [9, 10, 31]. Since
the remaining majority of 22 outpatients and eight inpa-
tients were treated orally from the beginning and only a
single dose of antibiotic given intravenously, the patients in
these two subgroups were comparable in terms of antibiotic
therapy. Importantly, this strategy is highly possible for
outpatient care, as indicated in our study. Therefore, the
route of antibiotic application itself would not have made
outpatient therapy impossible, which would confirm our
conclusion that outpatient treatment was, indeed, under-
utilised. Despite the absence of a significant difference in
antibiotic use, there are still discrepancies (e.g. observa-
tion, nursing care, nutrition, risk of infection etc.) in terms
of the general management between the ‘real’ hospital and
‘virtual’ home.
The knowledge from this survey provides the basis for
an ongoing interventional clinical trial with serially mea-
sured proADM, where the different triage pathways are
tested in real life. We did not separate patients according to
different entities of UTI but used the same triage algorithm
for all of them. Of note, more patients with pyelonephritis
(87 %) than cystitis (61 %) were admitted.
One of the strengths of our study is the innovative idea
of biomarker-enhanced triage for UTI. We have shown that
biomarkers can be used not only for the diagnosis-making
process, but also could help to decide whether the patient
should be admitted or not. We included all consecutive
patients without exclusion criteria in order to make our
results applicable to an unrestricted patient population. We
were also able to follow-up all patients for 30 days.
In conclusion, there is potential for biomarker-enhanced
triage to avoid not-indicated hospital admissions without
impairing safety. The addition of biomarkers to clinical
criteria might increase confidence in objective triage
decisions compared to clinical criteria alone.
As urea is more affected by renal function, proADM
might be more useful in patients with chronic renal insuf-
ficiency. The LOS might be shortened if clinical stability
criteria are assessed daily.
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